This week, we will discuss Inaxaplin for APOL1 mediated kidney disease (AMKD). Taking the octopus by the horns.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.